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Introduction
Infections of the cornea can lead to 
corneal opacity and blindness if not 
identified quickly and managed appropri-
ately. The terms infective keratitis, 
suppurative keratitis, and microbial 
keratitis are all used to describe suppu-
rative infections of the cornea. These are 
characterised by the presence of white or 
yellowish infiltrates in the corneal stroma, 
with or without an overlaying corneal 
epithelial defect, and associated with signs 
of inflammation (Figure 1). 
The common symptomatic complaints 
of patients with suppurative keratitis are 
as follows (all with varying degrees of 
severity):
• redness of the eye
• circum-corneal congestion (typically)
• pain
• blurring of vision
• photophobia
• watering of the eye. 
The aim of this article is to review both 
bacterial and fungal keratitis, with an 
emphasis on identification and management 
at the primary, secondary, and tertiary 
levels. Guidelines for referral will be 
suggested.
Fist steps in management
History taking
History taking is an important step in 
management of corneal infection. If there 
has been an injury, ask when and where the 
injury was sustained, what the patient was doing 
at the time of injury, whether or not he or she 
sought help following the injury, and what 
treatment – including traditional eye 
medications – may have been used.
A past history of conjunctivitis may 
suggest that the infection is secondary to a 
conjunctival pathogen.
Examination
1. Visual acuity
Visual acuity should always be recorded in all 
cooperative patients. If it is not possible to 
record the visual acuity of a child, for 
example, a note of this should be made. 
Vision should be recorded first in the 
unaffected eye, then in the affected eye; with 
or without glasses. This provides a useful 
guide regarding the prognosis and response 
to treatment. It is also important documen-
tation in the event of medico-legal issues.
2. Examination of the cornea
A torch with a good source of focused light 
and a loupe for magnification are essential. 
A slit lamp microscope, if available, is 
always helpful, but not absolutely essential.
Another essential tool is fluorescein dye, 
either in a sterile strip or a sterile solution. 
Fluorescein stains any part of the cornea 
that has lost the epithelium, even due to a 
trivial injury, and appears brilliant green 
when viewed under blue light (Figure 3). 
3. Corneal scrape
Diagnosis should be confirmed by obtaining 
a corneal scraping from the corneal lesion 
and subjecting it to laboratory testing at 
secondary or tertiary eye care facilities. 
See article on page 42.
Management at primary 
level
A suppurative corneal ulcer is an ophthalmic 
emergency which should be referred to the 
nearest eye centre for proper management. 
The following are useful guidelines when 
referring the patient to the secondary eye 
care centre.
• Do apply antibiotic drops or ointment
• Do instruct patients and/or their 
accompanying persons to apply drops 
frequently until patients arrive at the 
centre
• Do instruct patients and/or their 
accompanying persons to avoid traditional 
medicines.
• Do not give systemic antibiotics; they are 
not helpful
• Do not use steroid drops and/or ointment; 
they can be dangerous
• Do not routinely patch the eye; it is not 
necessary.
Management at secondary 
level
More complete management of corneal 
infections begins at the secondary level of 
eye care where there is an ophthalmologist 
and/or an ophthalmic assistant, or a physician 
trained in managing common eye diseases.
At the secondary level: 
• A corneal scraping should be taken (see 
page 42). 
• The patient should be admitted to the 
hospital to ensure adequate treatment 
and frequent follow-up.
Specific initial treatment
No fungal elements seen
• instil cefazolin 5% and gentamicin 
1.4% drops hourly. 
• Ciprofloxacin or ofloxacin is a good 
substitute for gentamicin and cephazolin. 
If it is not possible to administer hourly drops, 
a subconjunctival injection can be given.
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Figure 2. A bacterial ulcer. The eye is very 
red and inflamed. Note the ring infiltrate 
in the cornea and a large hypopyon in the 
anterior chamber. 
Figure 3. Fluorescein staining
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Figure 1. A severe bacterial ulcer caused 
by Pseudomonas sp. The gram negative 
(-ve) bacillus can cause complete 
destruction of the cornea within a few 
days. This cornea is at risk of perforation.
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Continues overleaf ➤
CEHJ71_OA.indd   39 13/01/2010   12:1440 COMMUnIty EyE HEaLtH JOURnaL | VOL 22 ISSUE 71 | DECEMBER 2009
Fungal elements seen
• Natamycin 5% drops hourly or freshly 
reconstituted amphotericin-B 0.15% as 
drops hourly. Antibiotics may have a 
limited role to play in such cases and may 
occasionally be harmful. Clinical judgment 
correlated with laboratory tests constitute 
the best guide in such cases.
Adjunctive treatment
• Atropine 1% or homatropine 2% could 
be used twice a day to dilate the pupil; 
this helps to prevent synechiae and 
relieve pain
• Oral analgesics will help to minimise pain
• Anti-glaucoma medication may be 
advisable if the intraocular pressure is high
• Vitamin A supplementation may be helpful, 
particularly in countries where Vitamin A 
deficiency is markedly prevalent. 
Five a’s are a useful acronym to remember: 
antibiotic/antifungal, atropine, analgesics, 
anti-glaucoma medications, and Vitamin a. 
Subsequent management 
Suppurative keratitis patients should be 
hospitalised and examined daily, if possible 
with a slit lamp, so that their response to 
treatment can be evaluated and the frequency 
of antibiotics adjusted accordingly. 
Reduce the frequency of antibiotic 
administration when the patient experi-
ences symptomatic improvement (less 
tearing and photophobia, relief from pain, 
and improvement in vision) and when the 
ulcer shows signs of improvement:
• decrease in lid oedema 
• decrease in conjunctival chemosis and 
bulbar conjunctival injection 
• reduction in density of the infiltrate and 
area of epithelial ulceration 
• haziness of the perimeter of the ulcer and 
of the stromal infiltrate 
• decrease in inflammation; cells, fibrin, 
and level of hypopyon 
• dilatation of pupil.
In the case of bacterial infection, the inflam-
matory reaction may be enhanced by 
endotoxin release during the first 48 hours 
of treatment; however, definite progression 
at this stage is unusual and implies that 
either the organisms are resistant to 
therapy, or the patient is not instilling the 
drops as prescribed.1 If the patient is judged 
to be improving, the dose of antibiotics and/
or antifungal drops should be reduced from 
hourly, to two-hourly, then four-hourly over 
the next two weeks in case of bacterial 
ulcers. For fungal ulcers, treatment should 
be continued with three-hourly drops for at 
least three weeks. 
Guidelines for referral to a tertiary 
centre
Immediate referral on presentation if:
• the ulcer is in an only eye
• the patient is a child 
• there is impending or actual perforation
• a fungal corneal ulcer is suspected but KOH 
or other fungal stains are not available.
Following initial treatment: if cases of 
bacterial ulcer fail to show any improvement 
within three days, and fungal ulcers within a 
week, patients should be referred to a 
tertiary care centre.
Management of corneal 
ulcer at tertiary level 
Many tertiary eye care centers have their 
own protocol for the management of 
corneal ulcer. The management suggested 
is based on a WHO recommendation for 
suitable modification according to 
circumstances.2
History, examination, and recording 
of findings
By the time patients have reached a 
tertiary centre, they will have travelled from 
one place to another with attendant 
hassles, received several treatments, may 
have lost faith in eye care personnel, and 
may already have run out of money, partic-
ularly in low-income countries. Attending to 
this situation is critically important in the 
overall care of corneal ulcer patients. 
A careful history of the development of 
the disease may point to the existence of 
an underlying predisposing condition such 
as diabetes mellitus, immunosuppression 
due to local or systemic steroids (or other 
immunosuppressants), dacryocystitis, or 
other ocular conditions. A full list of drugs 
used by the patient should be obtained to 
ensure that drugs which have not helped in 
the past are not repeated; this may also 
help to discover possible drug allergies. 
Findings should be carefully noted on a 
standard form.
A meticulous corneal scraping subjected 
to laboratory processing often provides a 
sound guideline to treatment. See page 42.
Hospitalisation 
This provides patients with rest and 
adequate medication; they can also receive 
frequent follow-up, management of 
systemic problems such as diabetes, and 
further surgical intervention, if warranted.
Treatment
The initial treatment depends on the results 
of the corneal scrape and the local pattern 
of pathogens and antibiotic resistance.
• If microscopy is negative, or it is not 
possible to perform a corneal scrape, or 
Gram-positive or Gram-negative bacteria 
are visualised, treat the patient with 
antibiotic eyedrops. Use either a 
combination of cefazolin 5% and 
gentamycin 1.4%, or fluoroquinolone 
monotherapy (eg. ciprfloxacin 0.3% or 
ofloxacin 0.3%). Drops should be given 
hourly to begin with for two days and then 
tapered, based on response.
• If microscopy reveals fungal hyphae, 
topical natamycin 5%, econazole 1% or 
amphotericin-B 0.15% should be used 
hourly for a week and then tapered. 
• If the ulcer seems to respond well to 
treatment, continue therapy as before for 
two weeks for a bacterial ulcer and three 
weeks or more for fungal ulcer.
• If the response is poor and the culture 
shows growth of an organism, the choice of 
antibiotic is guided by the sensitivity reports.
Figure 3. Subtotal 
fungal ulcer
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antibiotic Method Final concentration
Cefazolin/cefuroxime Add 10 ml sterile water to 500 mg 
cefazolin powder; mix and use as topical 
drops. Shelf life: 5 days
50 mg/ml (5%)
Gentamicin 
(tobramycin)
Add 2 ml parenteral gentamicin (40 mg/
ml) to a 5 ml bottle of commercial 
ophthalmic gentamicin (3 mg/ml) 
14 mg/ml (1.4%)
Penicillin G  Add 10 ml of artificial tears to a 1 million 
unit vial of Penicillin G powder; mix, 
remove, and place into empty artificial 
tear bottle or xylocaine vials (30 ml)
100,000 units/ml
Vancomycin  Add 10 ml sterile water to a 500 mg vial 
of vancomycin powder; mix, add sterile 
cap, and use
50 mg/ml (5%)
Amikacin Add 2 ml of parenteral amikacin 
containing 200 mg to 8 ml artificial tears 
or sterile water in a sterile empty vial.
20 mg/ml (2%)
Table 1. Preparation of fortified antibiotic eye drops
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are available for systemic mycoses, only few 
are effective for treatment of corneal ulcers. 
The commonly recommended drugs are 
given in Table 2.
However, except for natamycin and 
fluconazole, others are not available 
commercially for topical ocular use. The 
other antifungals have to be prepared using 
commercially available injectable forms 
such as amphotericin-B, miconazole, or 
raw materials such as clotrimazole and 
voriconazole. 
Other agents such as polyhexamethylene 
biguanide (PHMB) 0.02%, chlorhexidine 
0.02%, povidone iodine 1.5 to 5% and 
silver sulfadiazine 1% have been reported to 
possess variable antifungal activity and may 
be used if other drugs are not available.
Natamycin 5% suspension is recom-
mended for treatment of most cases of 
filamentous fungal keratitis, particularly 
those caused by Fusarium sp. Topical 
miconazole 1% (not commercially available 
for topical use) can be used as adjunct or 
supportive therapy. Most clinical and 
experimental evidence suggests that topical 
amphotericin-B (0.15 to 0.5%) is the 
most efficacious agent available to treat 
yeast keratitis. Amphotericin-B is also 
recommended for fungal keratitis caused 
by Aspergillus sp. Oral ketaconazole
(200–600 mg/day) may be considered as 
an adjunctive therapy in more severe fungal 
keratitis due to filamentous fungus. Oral 
fluconazole (200–400 mg  per day) has 
been used successfully for severe keratitis 
caused by yeasts. Oral itraconazole 
(200 mg/day) has broad-spectrum activity 
against all Aspergillus sp. and Candida but 
has variable activity against Fusarium sp.
Fungal infection of the deep corneal 
stroma may not respond to topical 
antifungal therapy because of poor 
penetration of these agents in the presence 
of an intact epithelium. It has been 
reported that a 5 mm epithelial debri-
dement (as a diagnostic scraping or 
therapeutic procedure) greatly enhances 
the penetration of antifungal drugs. 
Animal experiments indicate that 
frequent topical application (every five 
minutes) for an hour can readily achieve 
therapeutic level. 
Surgical management 
The range of surgical interventions 
available for management of corneal ulcer 
may include debridement, corneal biopsy, 
tissue adhesives, conjunctival flap, 
tarsorraphy, or therapeutic corneal graft. 
Evisceration of the eye is performed for 
severe pain, panophthalmitis, or life- 
threatening complications. 
Tarsorrhaphy
This is an old surgical technique that is still 
very useful today. In suppurative keratitis 
due to fungal and bacterial infections, 
tarsorrhapy is effective in promoting 
healing, provided the ulcer has been steri-
lised by effective antibacterial and/or 
antifungal treatment. Following central 
tarsorrhaphy, it can be difficult to instil drops 
and to see the cornea, so it is vital to ensure 
that the infection is under control before 
closing the eyelids. However, tarsorrhaphy 
often leads to rapid resolution of persistent 
epithelial defects, whatever the underlying 
cause. Once tarsorrhaphy is performed it is 
left in place for at least one to three 
months. There are different surgical 
techniques which are described well in 
many standard ophthalmic text books; 
however, simply suturing the lids together 
with a non-absorbable stitch can be 
effective. 
Conjunctival flap
The principle of this technique is to 
promote healing of a corneal lesion by 
providing adequate nutrition through the 
conjunctival blood vessels. The flap could 
be three types:
 
1 A total flap covering the entire cornea, 
called Gunderson’s flap. 
2 A pedicle (racquet) flap. A pedicle flap 
carries its own blood supply from the 
limbus and is useful for ulcers near the 
limbus.
3 A bucket handle flap. This carries its 
blood supply from both ends of the flap 
and may be less likely to retract. It is 
more useful for central corneal ulcers.
This procedure can be performed under 
local anaesthesia. Harvesting adequate 
bulbar conjunctiva in eyes which have had 
previous surgery may be difficult. The flap 
should be as thin as possible, with minimal 
adherent subconjunctival tissue. Following 
removal of any remaining corneal 
epithelium, the flap should be sutured to the 
cornea with 10-0 nylon sutures. 
The conjunctival flap promotes healing by 
vascularisation. It is particularly useful in 
patients with impending perforation, when it 
may preserve the globe and allow subse-
quent corneal grafting. However, a flap may 
limit the penetration of topical antibiotics, 
so it should only be performed once the 
ulcer has been sterilised and the infection 
brought under control. 
Conclusion
Management of suppurative keratitis 
remains a major challenge worldwide, more 
so in low- and middle-income countries with 
inadequate health care resources. Although 
the outcome of treatment has improved 
significantly, many patients continue to 
deteriorate in spite of the best treatment 
that can be offered. The continued 
emergence of strains of microorganisms 
that are resistant to an ever-expanding 
range of antimicrobials poses an additional 
challenge. Further research related to 
prevention of suppurative keratitis and 
enhancing host resistance are two worth-
while goals to pursue. Large-scale public 
education programmes to sensitise those at 
risk of suppurative keratitis, and to 
encourage earlier presentation, should be 
undertaken. Coupled with this, education of 
practioners, general physicians, and other 
health workers, as well as general ophthal-
mologists, will go a long way towards 
ensuring correct diagnosis, appropriate 
treatment, and timely referral before 
extensive damage to the cornea occurs. 
Management of corneal abrasions at 
primary care levels within 48 hours has 
been demonstrated by various studies to be 
the best way to prevent corneal ulcers in 
low- and middle-income countries.3-6  This 
could be adopted in any population and is 
cost effective both for health providers and 
the patient. 
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Drug topical Systemic
Amphotericin-B 0.15–0.5% drops IV infusion
Natamycin 5% drops Not available
Econazole 2% drops  Not available
Voricanozole 1% drops Oral tablets 100–200 mg/day 
Ketoconazole 2% drops Oral tablets 200–600 mg/day
Miconazole 1–2% drops Intravenous injection
Clotrimazole 1–2% ointment Not available
Fluconazole 0.2–0.3% drops Oral tablets 200 mg/day 
Table 2. Commonly recommended antifungal drugs
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